Recursion Pharmaceuticals, Inc. $RXRX Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP cut its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 6.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 107,476 shares of the company’s stock after selling 7,469 shares during the period. Wellington Management Group LLP’s holdings in Recursion Pharmaceuticals were worth $569,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the company. ARK Investment Management LLC boosted its stake in shares of Recursion Pharmaceuticals by 7.6% in the first quarter. ARK Investment Management LLC now owns 34,815,502 shares of the company’s stock worth $184,174,000 after acquiring an additional 2,469,104 shares during the last quarter. Softbank Group CORP. purchased a new position in Recursion Pharmaceuticals during the fourth quarter worth approximately $99,152,000. Kinnevik AB publ lifted its position in Recursion Pharmaceuticals by 12.8% during the first quarter. Kinnevik AB publ now owns 13,434,171 shares of the company’s stock worth $71,067,000 after buying an additional 1,528,503 shares in the last quarter. Laurion Capital Management LP purchased a new position in Recursion Pharmaceuticals during the fourth quarter worth approximately $16,611,000. Finally, Northern Trust Corp lifted its position in Recursion Pharmaceuticals by 18.4% during the fourth quarter. Northern Trust Corp now owns 2,394,511 shares of the company’s stock worth $16,187,000 after buying an additional 371,886 shares in the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, insider Najat Khan sold 36,599 shares of Recursion Pharmaceuticals stock in a transaction on Monday, August 18th. The stock was sold at an average price of $5.52, for a total value of $202,026.48. Following the sale, the insider owned 668,197 shares in the company, valued at $3,688,447.44. The trade was a 5.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 8.43% of the stock is owned by corporate insiders.

Recursion Pharmaceuticals Price Performance

NASDAQ:RXRX opened at $4.70 on Tuesday. Recursion Pharmaceuticals, Inc. has a 52 week low of $3.79 and a 52 week high of $12.36. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $2.04 billion, a P/E ratio of -2.64 and a beta of 0.91. The stock’s fifty day moving average is $5.44 and its two-hundred day moving average is $5.59.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Tuesday, August 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The business had revenue of $19.10 million during the quarter, compared to analysts’ expectations of $15.38 million. During the same quarter in the prior year, the firm earned ($0.40) EPS. Recursion Pharmaceuticals’s revenue for the quarter was up 33.3% compared to the same quarter last year. Equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Analyst Ratings Changes

RXRX has been the topic of a number of analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Tuesday, July 8th. Morgan Stanley initiated coverage on Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They set an “equal weight” rating and a $5.00 price objective on the stock. Two analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $7.00.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.